Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report.

Acute lymphoblastic leukemia Hematopoietic stem cell transplantation Inotuzumab ozogamicin Posttransplant cyclophosphamide Sinusoidal obstruction syndrome

Journal

Leukemia research reports
ISSN: 2213-0489
Titre abrégé: Leuk Res Rep
Pays: England
ID NLM: 101608906

Informations de publication

Date de publication:
2021
Historique:
received: 25 03 2021
accepted: 18 04 2021
entrez: 19 5 2021
pubmed: 20 5 2021
medline: 20 5 2021
Statut: epublish

Résumé

Owing to the poor prognosis of relapsed or refractory acute lymphoblastic leukemia (ALL), hematopoietic stem cell transplantation (HSCT) followed by effective salvage therapy is required. Inotuzumab ozogamicin (INO) was developed for ALL refractory to standard chemotherapy. However, previous reports suggest that sinusoidal obstruction syndrome (SOS) risk increases in patients with HSCT receiving INO, especially with dual alkylating agents. We report a case of relapsed Philadelphia chromosome-negative B-ALL where the patient underwent haploidentical HSCT using fludarabine/total body irradiation conditioning and posttransplant cyclophosphamide. Successful engraftment was achieved without SOS development.

Identifiants

pubmed: 34007785
doi: 10.1016/j.lrr.2021.100241
pii: S2213-0489(21)00008-X
pmc: PMC8111671
doi:

Types de publication

Case Reports

Langues

eng

Pagination

100241

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Biol Blood Marrow Transplant. 2010 Feb;16(2):157-68
pubmed: 19766729
Biol Blood Marrow Transplant. 2019 Nov;25(11):2211-2216
pubmed: 31247313
Hepatology. 2010 Apr;51(4):1450-60
pubmed: 20373370
N Engl J Med. 2016 Aug 25;375(8):740-53
pubmed: 27292104
Biol Blood Marrow Transplant. 2019 Sep;25(9):1720-1729
pubmed: 31039409
Lancet Haematol. 2017 Aug;4(8):e387-e398
pubmed: 28687420
Biol Blood Marrow Transplant. 2018 Sep;24(9):1896-1900
pubmed: 29803752
N Engl J Med. 2017 Mar 2;376(9):836-847
pubmed: 28249141
Bone Marrow Transplant. 2018 Apr;53(4):449-456
pubmed: 29330398

Auteurs

Masaya Abe (M)

Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Nobuharu Fujii (N)

Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.
Department of Transfusion Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Kentaro Mizuhara (K)

Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Tomohiro Urata (T)

Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Yuichi Sumii (Y)

Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Yuki Fujiwara (Y)

Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Keisuke Seike (K)

Department of Transfusion Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Yasuhisa Sando (Y)

Department of Transfusion Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Makoto Nakamura (M)

Department of Transfusion Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Keiko Fujii (K)

Department of Transfusion Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Kyosuke Saeki (K)

Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Yusuke Meguri (Y)

Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Noboru Asada (N)

Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Daisuke Ennishi (D)

Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Hisakazu Nishimori (H)

Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Ken-Ichi Matsuoka (KI)

Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Yoshinobu Maeda (Y)

Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.

Classifications MeSH